NCT06224907View on ClinicalTrials.gov

Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia A

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2029

Conditions
Hemophilia A
Interventions
BIOLOGICAL

Valoctocogene roxaparvovec

Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A

Trial Locations (4)

078-8510

Asahikawa Medical University Hospital, Hokkaido

350-0495

Saitama Medical University Hospital, Saitama

466-8560

Nagoya University Hospital, Aichi

160-0023

Tokyo Medical University Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY